The Federal Circuit’s recent denial of Cellect’s en banc petition leaves for another day clarity with respect to the interplay between obviousness-type double patenting and […]

In Re: Cellect, LLC  Decided August 28, 2023 Nearly a decade ago, the Federal Circuit held that “the doctrine of obviousness-type double patenting continues to […]

Written description: a death knell to genus claims in biotechnology Brian M Gummow, Alison Care, Karen Mangasarian and James F Haley Jr Haley Guiliano LLP 18 August 2022 Shutterstock\Pixels […]

The Unified Patent Court finally looks like it will be up and running in Europe by the end of 2022 or in early 2023, after […]

A new referral made to the Enlarged Board of Appeal, G2/21, is expected to provide clarity and consistency on the issue of the use of […]

It has been nearly six months since the EPO updated the Guidelines for Examination at the European Patent Office (“the Guidelines”).   We take a look […]

Supplementary protection certificates (SPCs) allow for up to five and half years of additional patent protection for a medicinal product that has been authorised to […]

With the passing of the Trademark Modernization Act of 2020 (TMA), trademark stakeholders will need to familiarize themselves with changes to the Lanham Act, as […]

The end of the BREXIT transition period has no effect on European patents or patent applications. The European Patent Office (EPO) is European in name […]

A number of IP rights that apply across the European Union no longer apply to the United Kingdom, now that it has left the EU […]